Cann Global need to provide shareholders with additional information on what they will make on the sale of Canntab, if they want new investor to buy in. We have pharmacy's, hospital and CMOS, how long is this batch going to last before repurchasing more Canntab, we have the rights for Asia, who and how are we going to market that. Remembering 50/50, all sales is a 50/50. It still needs to be sold.